Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Forte Capital LLC ADV

Forte Capital LLC ADV lessened its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 43,117 shares of the medical equipment provider’s stock after selling 1,307 shares during the quarter. Intuitive Surgical makes up about 2.0% of Forte Capital LLC ADV’s portfolio, making the stock its 15th biggest holding. Forte Capital LLC ADV’s holdings in Intuitive Surgical were worth $14,546,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ISRG. First National Trust Co raised its holdings in Intuitive Surgical by 3.8% in the 4th quarter. First National Trust Co now owns 3,127 shares of the medical equipment provider’s stock valued at $1,055,000 after acquiring an additional 115 shares during the last quarter. AJOVista LLC acquired a new position in Intuitive Surgical during the fourth quarter worth $200,000. Provence Wealth Management Group purchased a new position in shares of Intuitive Surgical during the fourth quarter worth $276,000. Blue Fin Capital Inc. raised its holdings in shares of Intuitive Surgical by 8.0% in the 4th quarter. Blue Fin Capital Inc. now owns 864 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 64 shares during the period. Finally, Legacy Financial Advisors Inc. lifted its stake in Intuitive Surgical by 13.9% during the 4th quarter. Legacy Financial Advisors Inc. now owns 1,774 shares of the medical equipment provider’s stock worth $598,000 after acquiring an additional 216 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Intuitive Surgical stock traded up $3.71 during mid-day trading on Friday, reaching $381.36. 1,028,858 shares of the company were exchanged, compared to its average volume of 1,492,254. The firm’s 50-day simple moving average is $385.40 and its two-hundred day simple moving average is $349.30. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $403.76. The firm has a market cap of $135.27 billion, a PE ratio of 68.84, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.00 EPS. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insiders Place Their Bets

In other news, President David J. Rosa sold 80,710 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the sale, the president now directly owns 163,399 shares in the company, valued at approximately $63,607,962.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 481 shares of Intuitive Surgical stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $386.09, for a total transaction of $185,709.29. Following the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at $115,054.82. The sale was disclosed in a filing with the SEC, which is available at this link. Also, President David J. Rosa sold 80,710 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total transaction of $31,418,788.80. Following the completion of the sale, the president now directly owns 163,399 shares of the company’s stock, valued at approximately $63,607,962.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 226,928 shares of company stock worth $87,833,828. Corporate insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Raymond James boosted their price target on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Truist Financial raised their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Citigroup upped their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada lifted their target price on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Finally, Mizuho upped their price target on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.